- Home
- PRME vs DJCO Comparison
PRME vs DJCO Comparison
Compare PRME & DJCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | DJCO |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 706.2M |
| IPO Year | 2022 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PRME | DJCO |
|---|---|---|
| Price | $3.54 | $515.50 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.56 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 22.0K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 43.50 |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $41,384,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.18 | $348.63 |
| 52 Week High | $6.94 | $674.75 |
Technical Indicators
Market Signals| Indicator | PRME | DJCO |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 58.10 |
| Support Level | $3.15 | $507.78 |
| Resistance Level | $3.60 | $559.97 |
| Average True Range (ATR) | 0.23 | 19.62 |
| MACD | 0.07 | 5.29 |
| Stochastic Oscillator | 93.44 | 84.95 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.